Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial vicTORia. 18. Oktober 2018 Decker, T., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Lerchenmüller, C., 2018. Oncol Res Treat 41 (suppl4)(V491), 158–159. Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2. M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018. Oncol Res Treat 41 (suppl 4)(P610). Weiterlesen Real World Molecular Testing in Patients with EGFR Mutation-Positive Locally Advanced or Advanced NSCLC in routine practice in Germany – Interim results of the clinical registry PANORAMA. Griesinger, F., Büttner, R., Deppermann, K.-M., Reinmuth, N., Schütte, W., Thomas, M., Wroblewski, M., Schumann, C., 2018. Oncol Res Treat 2018;41(suppl 4): V753, S.249… Weiterlesen